Abstract
Since COVID-19 was first identified in China in 2019, the SARS-CoV-2 virus has mutated and given rise to a large number of variants. A range of non-pharmaceutical interventions have been deployed against the virus in an effort to save lives and reduce pressure on health-care systems. These interventions may have favoured some variants over others. Despite this possibility, there has thus far been very little work investigating the impact of such interventions on the evolution of the virus.
Using mathematical and computational models, we investigate the impact of a lockdown specifically, for the case in which two SARS-CoV-2 variants are circulating simultaneously in a population. We find that under certain conditions, lockdowns disrupt the competition between variants in such a way that highly transmissible variants with long infectious periods are selected for, ultimately leading to more cases overall than would have occurred without the lockdown, due to larger second waves of cases.
These are the results of a modelling study and we do not claim to have found evidence of such unfavourable selection effects occurring in reality. On the other hand, our results are consistent with evolutionary theory and suggest that the selective effects of non-pharmaceutical interventions deserve greater scrutiny.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced are available online at: https://github.com/abm-covid-lux/multi_strain_abmlux_fast
